{"id":52503,"date":"2024-07-23T15:38:52","date_gmt":"2024-07-23T14:38:52","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=52503"},"modified":"2024-11-05T15:39:51","modified_gmt":"2024-11-05T15:39:51","slug":"chiesi-group-releases-2023-sustainability-report","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/chiesi-group-releases-2023-sustainability-report\/52503\/","title":{"rendered":"Chiesi Group releases 2023 sustainability report"},"content":{"rendered":"
The recent sustainability report focuses on four areas: Patients, Planet, People, and Prosperity.<\/p>\n
In 2023, Chiesi integrated its Shared Value & Sustainability and Global Strategy functions with key departments, forming the ‘Strategy, Sustainability, and Growth Unit.’<\/p>\n
This unit aims to drive economic evolution and sustainable growth by leveraging diverse skills and perspectives.<\/p>\n
Siham Imani, Head of the Unit, highlighted the importance of this integrative approach: “Uniting these departments and their diverse skills and perspectives, we’re pioneering a transversal approach to drive the company’s future economic evolution and sustainable growth.<\/p>\n
“Through this integrative governance, we utilise our collective expertise to innovate and foster positive societal and environmental impact.”<\/p>\n
Chiesi invested \u20ac720.8m (23.8% of sales) in Research and Development in 2023, holding over 6,200 global patents.<\/p>\n
The Group is constructing a Biotech Center of Excellence, opening in fall 2024, to develop and produce biological medicines.<\/p>\n
Chiesi introduced a unified Patient Journey Framework for continuous patient engagement and is working on a Health Equity strategy aligned with the UN Agenda 2030.<\/p>\n
Chiesi aims to achieve net zero greenhouse gas (GHG) emissions by 2035. In 2023, the company reduced Scope 1 and 2 GHG emissions by 39% compared to 2019.<\/p>\n
Chiesi is investing over \u20ac350m in a new pressurised metered dose inhaler (pMDI) to reduce its carbon footprint by 90%.<\/p>\n
The value chain is crucial in this effort, with Chiesi implementing the Code of Interdependence and earning the EcoVadis Platinum Medal for supplier performance.<\/p>\n
Chiesi fosters a positive work environment and is certified as a ‘Great Place to Work’ and ‘Top Employer.’<\/p>\n
The company closed the gender pay gap in 2022, becoming the first Italian pharmaceutical company\u00a0certified for Gender Equality by Bureau Veritas.<\/p>\n
Committed to equal career advancement for all genders by 2030, they’ve launched targeted programmes.<\/p>\n
This includes mentoring initiatives for women alongside comprehensive family-friendly policies.<\/p>\n
Flexible work arrangements, training for new parents, equitable and extended parental leave, and economic and childcare support empower employees to thrive both at work and at home.<\/p>\n
Recognising the connection between a healthy workforce and a healthy community, Chiesi’s strong corporate volunteering programme is another pillar of their commitment.<\/p>\n
In 2023, over 2,000 employees (a remarkable 30.5% of the workforce) participated, contributing a staggering 16,656 hours \u2013 a 77.5% increase from 2022.<\/p>\n
This dedication demonstrates Chiesi’s belief that employee wellbeing and community engagement go hand-in-hand.<\/p>\n
In 2023, Chiesi distributed 77% of its economic value to stakeholders and reinvested 23% for long-term growth.<\/p>\n